A comparative study of second trimester termination of pregnancy with mifepristone and misoprostol vs misoprostol alone in 50 cases
The aim: To study the efficacy and safety of combined mifepristone and misoprostol used in second-trimester abortion(≥ 12 and ≤ 20 weeks) in comparison with only vaginal misoprostol.
Materials and methods: This study was a prospective comparative randomised clinical study in women attending hospitals in need of a second-trimester abortion, i.e., 12–20 weeks of pregnancy were taken up and divided as Group A – 50 women with mifeprisptone and misoprostol, Group B – 50 women with misoprostol alone Results were analysed according to age, parity, gestational age, average dose of misoprostol required for complete abortion, Induction abortion interval, completeness of abortion, side effects and mean days of hospital stay.
Results: Demographic details are comparable and insignificant in the comparison. The average dose of misoprostol (mcg) required for the completeness of abortion in group A is 596±28.28 mcg, and in group B, it is 1148±160.66 mcg (p<0.001) which is statistically significant. In the present study, the induction abortion interval is significantly less in group A compared to group B, with p<0.001. In addition, 10 out of 50 patients in group A aborted within 7 hours, whereas none in group B. Mean duration of hospital stay in group A is 24 hours. In group B, it is 34.82 hours which is statistically significant with a p-value of <0.001. 12 patients in group A and 26 in group B had side effects like nausea, vomiting, fever, headache and diarrhoea. 8 % of group A and 20 % of group B had a fever. These patients were treated with antipyretics. 6 % in group A and 14 % in group B had nausea and vomiting and were treated with antiemetics. 4 % in group A and 8 % in group B had diarrhoea and were treated with antimotility drugs. 6 % in group A and 10 % in group B had a headache; these patients were treated with NSAIDs.
Conclusions: The combination of mifepristone and misoprostol is a highly effective and safe method for second-trimester termination of pregnancy. The amount of misoprostol needed to accomplish the abortion, and the severity of the adverse effects are lower in the mifepristone-primed group than in the misoprostol-alone group. Since there are fewer difficulties, this approach can be employed in hospitals with high patient density.
WHO model list of essential medicines (2017). Geneva: World Health Organization. Available at: http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf Last accessed: 05.11.2018
Melese, T., Habte, D., Tsima, B. M., Mogobe, K. D., Nassali, M. N. (2018). Management of post abortion complications in Botswana -The need for a standardized approach. PLOS ONE, 13 (2), e0192438. doi: https://doi.org/10.1371/journal.pone.0192438
Chavan, S. V., Mahajan, N. N., Tilve, A. G. (2019). Randomized comparison of vaginal and sublingual misoprostol with mifepristone priming in termination of second trimester pregnancy. International Journal of Research in Medical Sciences, 7 (10), 3869–3873. doi: https://doi.org/10.18203/2320-6012.ijrms20194323
Medical management of abortion (2018). Geneva: World Health Organization, 72.
Saxena, P., Jaiswal, N., Kabra, S. L., Kadam, V. K., Saxena, V. (2021). Second trimester termination of pregnancy with misoprostol alone and misoprostol with isosorbide mononitrate: a comparative study. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 10 (3), 971–974. doi: https://doi.org/10.18203/2320-1770.ijrcog20210718
Madhuri, N., Veena, G. R., Manjunath, G. H. (2016). Randomised comparison of oral and vaginal misoprostol when combined with mifepristone for termination of second trimester pregnancy. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 5 (2), 509–513. doi: https://doi.org/10.18203/2320-1770.ijrcog20160400
Jahagirdar, S., Junghare, P. (2015). Safety and efficacy of simultaneous use of Mifepristone and Misoprostol in second trimester termination of pregnancy. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 5 (4), 1359–1363. doi: https://doi.org/10.18203/2320-1770.ijrcog20150711
Kulkarni, K. K. (2013). Pre-induction with Mifepristone for Second Trimester Termination of Pregnancy. The Journal of Obstetrics and Gynecology of India, 64 (2), 102–104. doi: https://doi.org/10.1007/s13224-013-0472-5
Farhadifar, F., Shahgheibi, S., Moradi, G., Memar, F. M. (2016). Comparison of Oral Versus Vaginal Misoprostol for Legal Abortion in Iranian Women. Journal of Clinical Gynecology and Obstetrics, 5 (2), 59–63. doi: https://doi.org/10.14740/jcgo406e
Nagaria, T., Sirmor, N. (2011). Misoprostol Vs Mifepristone and Misoprostol in Second Trimester Termination of Pregnancy. The Journal of Obstetrics and Gynecology of India, 61 (6), 659–662. doi: https://doi.org/10.1007/s13224-011-0118-4
Akkenapally, P. L. (2016). A Comparative Study of Misoprostol Only and Mifepristone Plus Misoprostol in Second Trimester Termination of Pregnancy. The Journal of Obstetrics and Gynecology of India, 66 (S1), 251–257. doi: https://doi.org/10.1007/s13224-016-0869-z
Patil, N. G., Gupta, P., Hittinhalli, M. D., Mudanur, S. R., Tehalia, M. K. J., Nemagouda, A. S., Kori, S. S. (2017). A randomised controlled trial to compare the efficacy of preinduction with mifepristone 12 hours versus 24 hours prior for second trimister pregnancy termination. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6 (8), 3628. doi: https://doi.org/10.18203/2320-1770.ijrcog20173498
Patil, S. B., Biliangady, H. N. (2014). A Comparative Study using Combination of Mifepristone and Misoprostol and Single Drug Misoprostol only for Second Trimester Abortion. Scholars Journal of Applied Medical Sciences, 2 (2D), 840–843.
Wedisinghe, L., Elsandabesee, D. (2010). Flexible mifepristone and misoprostol administration interval for first-trimester medical termination. Contraception, 81 (4), 269–274. doi: https://doi.org/10.1016/j.contraception.2009.09.007
Sindhuri, T. R., Samal, S., Gupta, S., Ghose, S. (2020). Effect of mifepristone misoprostol versus misoprostol in the management of intrauterine fetal death. Archives of Medicine and Health Sciences, 8 (2), 202–207.
Borgatta, L., Kapp, N. (2011). Labor induction abortion in the second trimester. Contraception, 84 (1), 4–18. doi: https://doi.org/10.1016/j.contraception.2011.02.005
Trivedi, K., Swati, A., Shrivastava, P., Singh, S. (2019). Mifepristone Followed by Prostaglandin Vs Prostaglandin alone for induction of Labour in Intrauterine Foetal Death at or more than 28 Weeks of Pregnancy. International Journal of Contemporary Medical Research, 6 (10). doi: https://doi.org/10.21276/ijcmr.2019.6.10.24
Maheshwari, S., Borgohain, D. (2017). Methods of induction of labor in intrauterine fetal demise: a comparative study. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6 (9), 3911–3914. doi: https://doi.org/10.18203/2320-1770.ijrcog20174033
Panda, S., Jha, V., Singh, S. (2013). Role of a combination of Mifepristone and Misoprostol versus misoprostol alone in Induction of labor in late intrauterine fetal death. Journal of Family and Reproductive Health, 7 (4), 177–179.
Hoda, A., Ali, M., Kulsoom, U. K. (2022). A Prospective Comparative Study of Mifepristone and Misoprostol vs Misoprostol Alone for Induction of Labor in Intrauterine Fetal Death. Journal of South Asian Federation of Obstetrics and Gynaecology, 13 (6), 355–358. doi: https://doi.org/10.5005/jp-journals-10006-1942
Copyright (c) 2022 Maloth Swathi, Ratnam Andallu, Manekar Balasaraswathi, Vederay Suvarna
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.